In support of improving patient care, Boston University Chobanian & Avedisian School of Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Boston University Chobanian & Avedisian School of Medicine designates this live internet activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Contact Hours: 2.5, of which 2.5 are eligible for pharmacology credit
Nurses will receive contact hours after completion of a post-test and evaluation.
This activity is approved for 2.5 CPE credit(s) under the ACPE universal activity number UAN JA0000185-0000-23-010-H08-P. The activity is available for credit claiming for up to 60 days after completion of the activity.
The AAFP has reviewed SCOPE of Pain: Safer/Competent Opioid Prescribing Education, and deemed it acceptable for AAFP credit. Term of approval is from 10/1/2023 to 9/30/2024. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Credit approval includes the following session(s):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points and patient safety MOC credit in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirement(s) of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.
By participating in the activity and claiming credit, you grant the Center for Continuing Education permission to submit your information to the ACCME, the conduit to the ABS.
This activity was planned in collaboration with our national partners, the Federation of State Medical Boards.
This activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies. Please see https://opioidanalgesicrems.com/Resources/Docs/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the US Food and Drug Administration.
Physicians, nurse practitioners, registered nurses, physician assistants, nurses, dentists, pharmacists, and allied health professionals whose practices manage acute and chronic pain.
At the conclusion of these activities, participants will be better able to:
Boston University Chobanian & Avedisian School of Medicine asks all individuals involved in the development and presentation of Accredited Continuing Education activities to disclose all financial relationships with ineligible companies. This information is disclosed to all activity participants prior to the start of the educational activity. Boston University Chobanian & Avedisian School of Medicine has procedures to mitigate all relevant financial relationships with ineligible companies. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.
In accordance with the Standards for Integrity and Independence in Accredited Continuing Education, all relevant financial relationships with ineligible companies that faculty, planners, authors and anyone who may be in control of content have been mitigated.
Daniel P. Alford, MD, MPH, FACP, FASAM (Course Director/Content Development)
Professor of Medicine
Associate Dean, Continuing Medical Education
Director, Clinical Addiction Research and Education (CARE) Unit
Boston University Chobanian & Avedisian School of Medicine | Boston Medical Center
Faculty member has no relevant financial relationships to disclose.
Melissa Weimer was a consultant for CVS Health. Other content development and planning committee members have no relevant financial relationships to disclose.
This presentation does include discussion of the off-label use of sublingual buprenorphine to treat pain. Sublingual buprenorphine has been FDA approved for addiction treatment but not pain treatment. This presentation does include discussion of the off-label use of clonidine and tizanidine to treat opioid withdrawal symptoms. Clonidine and tizanidine are not FDA approved for this use.
THIS CONTINUING MEDICAL EDUCATION PROGRAM IS INTENDED SOLELY FOR EDUCATIONAL PURPOSES FOR QUALIFIED HEALTH CARE PROFESSIONALS. THIS PROGRAM DOES NOT REPLACE YOUR HOME COUNTRY’S LAWS, REGULATIONS, AND GUIDELINES CONCERNING MEDICAL CARE AND DRUG PRESCRIPTION ACTIVITIES. IN NO EVENT SHALL BOSTON UNIVERSITY BE LIABLE FOR ANY DECISION MADE OR ACTION TAKEN IN RELIANCE ON THE INFORMATION CONTAINED IN THE PROGRAM. IN NO EVENT SHOULD THE INFORMATION CONTAINED IN THE PROGRAM BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE. NO PHYSICIAN-PATIENT RELATIONSHIP IS BEING ESTABLISHED.
Date of Original Release: 10/19/2023
Date of Expiration: 01/22/2024
SCOPE of Pain
© 2023 Trustees of Boston University. Site by Root802.